These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37460143)

  • 1. Zavegepant (Zavzpret) for acute treatment of migraine.
    Med Lett Drugs Ther; 2023 Jul; 65(1681):116-118. PubMed ID: 37460143
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs for migraine.
    Med Lett Drugs Ther; 2023 Jun; 65(1678):89-96. PubMed ID: 37266987
    [No Abstract]   [Full Text] [Related]  

  • 3. Rimegepant (Nurtec ODT) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 May; 62(1597):70-72. PubMed ID: 32555113
    [No Abstract]   [Full Text] [Related]  

  • 4. Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 Mar; 62(1593):35-39. PubMed ID: 32555120
    [No Abstract]   [Full Text] [Related]  

  • 5. Atogepant (Qulipta) for migraine prevention.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):169-171. PubMed ID: 35085204
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison table: Some drugs for migraine prevention in adults.
    Med Lett Drugs Ther; 2023 Jun; 65(1678):e100-e102. PubMed ID: 37266989
    [No Abstract]   [Full Text] [Related]  

  • 7. A new dihydroergotamine nasal spray (Trudhesa) for migraine.
    Med Lett Drugs Ther; 2021 Dec; 63(1640):204-207. PubMed ID: 35100240
    [No Abstract]   [Full Text] [Related]  

  • 8. Drugs for Migraine.
    Med Lett Drugs Ther; 2020 Oct; 62(1608):153-160. PubMed ID: 33434187
    [No Abstract]   [Full Text] [Related]  

  • 9. Eptinezumab (Vyepti) for migraine prevention.
    Med Lett Drugs Ther; 2020 Jun; 62(1599):85-87. PubMed ID: 32555116
    [No Abstract]   [Full Text] [Related]  

  • 10. Fremanezumab (Ajovy) and galcanezumab (Emgality) for migraine prevention.
    Med Lett Drugs Ther; 2018 Nov; 60(1559):177-180. PubMed ID: 30681655
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist.
    Joyner KR; Morgan KW
    Ann Pharmacother; 2021 Jun; 55(6):745-759. PubMed ID: 32993366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In brief: Erenumab (Aimovig) hypersensitivity.
    Med Lett Drugs Ther; 2019 Mar; 61(1568):48. PubMed ID: 31022159
    [No Abstract]   [Full Text] [Related]  

  • 13. The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review.
    Vig SJ; Garza J; Tao Y
    Headache; 2022 Nov; 62(10):1256-1263. PubMed ID: 35467013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In brief: Hypertension with erenumab (Aimovig).
    Med Lett Drugs Ther; 2021 Apr; 63(1621):56. PubMed ID: 33830970
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rimegepant: acute treatment for migraine headaches.
    Peters GL; Hennessey EK
    Pain Manag; 2021 May; 11(3):259-266. PubMed ID: 33550872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.
    Polavieja P; Belger M; Venkata SK; Wilhelm S; Johansson E
    J Headache Pain; 2022 Jul; 23(1):76. PubMed ID: 35790906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR; da Silva MRR
    Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis.
    Johnston K; Popoff E; Deighton A; Dabirvaziri P; Harris L; Thiry A; Croop R; Coric V; L'Italien G; Moren J
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):155-166. PubMed ID: 34148501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Migraine overview and summary of current and emerging treatment options.
    Peters GL
    Am J Manag Care; 2019 Jan; 25(2 Suppl):S23-S34. PubMed ID: 30681821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.